ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2092

No Significant Effect of Hepatitis B Virus Infection On Disease Activity, Synovitis or Joint Destruction in Rheumatoid Arthritis

Chan Juan Zou, Yan Hua Li, Ying Qian Mo, Lang Jing Zhu, Dong Hui Zheng, Jian Da Ma, Xia Ouyang and Lie Dai, Division of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: joint destruction, rheumatoid arthritis (RA) and synovitis

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects III: Infections/Risk Factors for Incident Rheumatoid Arthritis/Metrology/Classification/Biomarkers/Predictors of Rheumatolid Arthritis Activity & Severity

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The prevalence of chronic hepatitis B virus (HBV) infection is high in China. 4% patients with HBV infection can present with polyarthritis and positive rheumatic factor similar to RA, which implied similar pathogenic mechanism.We aimed to investigate the association between HBV infection and serological, radiological or histological disease status in RA.

Methods: 223 continuous hospitalized Chinese patients with RA were enrolled retrospectively. Clinical and laboratory data including HBV detection, and hand X ray were collected. Among 133 active RA patients, synovium was obtained by closed-needle biopsy from inflamed knee joint. Serial tissue sections were stained immunohistochemically for HBV surface antigen (HBsAg), CD79a, CD20, CD38, CD68, CD3, and CD34. Densities of positive-staining cells and synovitis score were determined.

Results: According to HBV infection status, 25/223 had chronic HBV infection (including 4 chronic hepatitis B and 21 HBV carriers), 72/223 had past HBV infection and 126/223 had no HBV infection. The prevalence of HBsAg positivity and chronic hepatitis B in RA was 11.2% and 1.7%, not significantly different with age-matched general Chinese population (8.7% from 2006 Chinese national epidemiological survey and 1.0% from 2005 local survey, respectively, P>0.05). Clinical parameters, DAS28 or Sharp scores showed no significant difference among chronic HBV infection, past HBV infection and no HBV infection groups in 206 active RA or 140 active RA patients without any corticosteroid or DMARDs treatment (all P>0.05). Synovial immunohistochemical staining showed negative HBsAg in 10 HBV carriers and 10 past HBV infection patients. Except for higher sublining CD3+ cell density in past HBV infection group, Krenn’s synovitis score, mean densities of sublining positive-staining cells (CD20, CD38, CD79a and CD68) and CD34+ microvessel counts showed no significant difference among RA patients with HBV carrier, past HBV infection or no HBV infection (all P>0.05).

Conclusion: The prevalence of HBV infection in RA patients was consistent with general Chinese population. Chronic HBV infection have no significant effect on disease activity, synovitis or joint destruction in RA, implying that chronic HBV infection may play neither promotive nor protective role in RA.


Disclosure:

C. J. Zou,
None;

Y. H. Li,
None;

Y. Q. Mo,
None;

L. J. Zhu,
None;

D. H. Zheng,
None;

J. D. Ma,
None;

X. Ouyang,
None;

L. Dai,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/no-significant-effect-of-hepatitis-b-virus-infection-on-disease-activity-synovitis-or-joint-destruction-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology